Document resource
Introduction The present study reports a multicentre experience of using hydrophilic polymer-coated (HPC) flow diverters in with prasugrel single antiplatelet therapy to treat Posterior Circulation Aneurysms (APC).Aim of study The objective of this study was to present the findings of a multicenter investigation of the use of p48/64 MW HPC devices in conjunction with prasugrel SAPT for the management of intracranial APCs.Method A prospectively maintained database was retrospectively reviewed to identify all cases of intracranial APC treated with the HPC coated FDs under SAPT (Prasugrel). The clinical presentation and outcomes, periprocedural and postprocedural complications, and degree of occlusion at follow-up (FU) were evaluated.Results A total of 74 patients were treated (45.9% of whom were female). Ischemic complications were experienced by two patients (2.7%) and was dependent on the use of FD. No cases of aneurysm rupture or hemorrhagic complications related to antiplatelet therapy, or the FD-treatment, were recorded. The rate of complete occlusion was 77.9% in the early FU period (3–6 months) and 90.3% in the initial 12-month period.Conclusion HPC coated flow diverters with prasugrel SAPT was associated with high safety in the treatment of ruptured and unruptured APC and high occlusion rates at early- and med-term FU.Conflict of Interest Yes i am a consultant for WallabyPhenox